Kilitch Drugs (India) Limited (KILITCH) AI Stock Analysis

• Market Cap: ₹5.92B
• Dividend Yield: N/A
• Average Volume (3M): 3.69K
• Price to Earnings (P/E): 19.9
• Beta (1Y): 0.96
• Revenue Growth: 37.51%
• EPS Growth: 122.52%
• Country: IN
• Employees: 168
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.84
• Shares Outstanding: 17,480,782
• 10 Day Avg. Volume: 2,427
• 30 Day Avg. Volume: 3,690
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹423.00
• Price Target Upside: 24.82% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: ₹423.00 ▲(24.82% Upside)

Kilitch Drugs' overall stock score is primarily influenced by its solid financial performance, despite some operational and cash flow challenges. The bearish technical indicators and fair valuation further moderate the score. The absence of earnings call data and corporate events means these factors do not impact the score.

Kilitch Drugs (India) Limited Business Overview & Revenue Model

Company Description

Kilitch Drugs (India) Limited (KILITCH) is a pharmaceutical company based in India that specializes in the research, development, manufacturing, and marketing of a wide range of pharmaceutical formulations. The company primarily focuses on injectable formulations, ophthalmic products, and other specialty pharmaceuticals. KILITCH serves both domestic and international markets, providing high-quality and cost-effective healthcare solutions.

How the Company Makes Money

Kilitch Drugs (India) Limited generates revenue through the sale of its pharmaceutical products, including injectable formulations and ophthalmic solutions, to a diverse clientele in both domestic and international markets. The company earns income by manufacturing and distributing generic and branded pharmaceutical products, leveraging its expertise in producing cost-effective medical solutions. Additionally, KILITCH may engage in strategic partnerships with other pharmaceutical companies to expand its product offerings and market reach, further contributing to its revenue streams. Revenue is also driven by contract manufacturing services provided to other pharmaceutical companies, thereby optimizing the utilization of its production facilities.

Kilitch Drugs (India) Limited Financial Statement Overview

Summary

Kilitch Drugs shows strong revenue growth and improved profit margins, indicating robust financial health. However, operational efficiency and cash flow management need improvement, as evidenced by the moderate EBIT and EBITDA margins and challenges in converting earnings into cash flow.

Income Statement

Kilitch Drugs has demonstrated robust revenue growth with a notable increase in total revenue from previous years. The gross profit margin is healthy, indicating effective cost management. Net profit margin has improved significantly, showcasing enhanced profitability. However, the EBIT and EBITDA margins, although positive, suggest room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet reflects a strong equity position with a favorable equity ratio. The debt-to-equity ratio is moderate, suggesting a balanced approach to leverage. Return on Equity (ROE) indicates a positive return on shareholder investments, although it could be further optimized. Overall, the balance sheet is stable but has potential for better utilization of assets.

Cash Flow

The cash flow statement shows challenges in free cash flow, with negative growth in recent periods due to increased capital expenditures. The operating cash flow to net income ratio is positive but indicates that the company is facing difficulties in translating earnings into cash flow. Improvements in cash management could enhance financial flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.98B	1.98B	1.54B	1.40B	1.14B	681.28M
Gross Profit	901.79M	937.39M	731.38M	624.64M	337.44M	300.07M
EBITDA	426.26M	426.26M	287.43M	206.50M	134.13M	79.85M
Net Income	263.18M	267.01M	146.01M	104.48M	73.67M	36.71M
Balance Sheet
Total Assets	3.13B	3.13B	2.40B	2.20B	2.10B	2.03B
Cash, Cash Equivalents and Short-Term Investments	593.98M	593.98M	690.19M	591.77M	572.43M	488.49M
Total Debt	494.24M	494.24M	316.46M	221.94M	204.32M	148.04M
Total Liabilities	1.12B	1.12B	643.88M	689.41M	695.55M	736.97M
Stockholders Equity	2.02B	2.02B	1.76B	1.52B	1.39B	1.27B
Cash Flow
Free Cash Flow	0.00	-293.31M	-65.97M	-12.26M	-24.19M	93.61M
Operating Cash Flow	0.00	175.42M	-1.46M	25.86M	57.83M	456.59M
Investing Cash Flow	0.00	-399.47M	-95.45M	79.15M	-152.50M	-375.69M
Financing Cash Flow	0.00	132.43M	88.07M	-7.16M	70.28M	16.14M

Kilitch Drugs (India) Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 338.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Negative. The current price of 338.9 is below the 20-day moving average (MA) of 358.20, below the 50-day MA of 399.15, and below the 200-day MA of 371.35, indicating a bearish trend. The MACD of -13.83 indicates Negative momentum. The RSI at 28.93 is Positive, neither overbought nor oversold. The STOCH value of 5.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KILITCH.

Kilitch Drugs (India) Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	67 Neutral	5.86B	10.92	8.08%	―	9.15%	88.32%
SAKAR	64 Neutral	7.83B	39.59	6.13%	―	21.65%	73.16%
INDSWFTLAB	58 Neutral	6.02B	2.90	21.35%	―	-68.96%	-30.30%
KILITCH	57 Neutral	₹5.92B	19.89	―	―	37.51%	122.52%
MEDICAMEQ	54 Neutral	4.13B	41.20	3.34%	0.33%	-9.90%	33.18%
NECLIFE	43 Neutral	3.26B	-1.81	-11.89%	―	-3.41%	-3028.44%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%